Supplementary Figure S3 from First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Figure S3. CT scans showing partial response to tuvusertib treatment in one patient with platinum- and PARP inhibitor-resistant BRCAwt ovarian cancer, receiving a dose of tuvusertib 150 mg BID 4 days on/3 days off.